1-3 of 3
Niranjan S. Rao, PhD
Close
Sort by
Journal Articles

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD, Sanjeeva Reddy, PhD, Gupta Sandeep, PhD, Nitin K Damle, PhD, Venkatesan M Aranapakam, PhD, Scott Thompson, PhD, Roger Smith, PhD, Terry Plasse, MD, Penelope Bristow, MS, Anthony Tolcher, MD, Kyriakos P Papadopoulos, MD, Amita Patnaik, MD, Drew W Rasco, MD
Journal: Blood
Blood (2015) 126 (23): 4009.
https://doi.org/10.1182/blood.V126.23.4009.4009
Published: 2015
Journal Articles

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,

Alexander E Perl, MD, Grace R Jeschke, Takashi Sato, Shiro Akinaga, Niranjan S. Rao, PhD, Maria R. Baer, MD, Mark J. Levis, MD, PhD, Martin Carroll, MD
Journal: Blood
Blood (2011) 118 (21): 3508.
https://doi.org/10.1182/blood.V118.21.3508.3508
Published: 2011
Journal Articles

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, Eric J. Feldman, MD, Judith E. Karp, MD, Keith W. Pratz, MD, Niranjan S. Rao, PhD, Shiro Akinaga, PhD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2967.
https://doi.org/10.1182/blood.V112.11.2967.2967
Published: 2008